Prediction of pathological complete response and prognosis in locally advanced rectal cancer

Table 2 Univariate analysis of pathologic complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Factor	Non-pCR (n = 86)	pCR (n = 42)	χ2	P value
Gender			0.64	0.422
Male	67	30
Female	19	12
Age group (yr)			0.015	0.902
≤ 60	44	21
> 60	42	21
BMI (kg/m2)			0.162	0.922
< 18.5	6	3
18.5-23.9	42	22
≥ 24	38	17
cT stage			0.575	0.448
cT3	69	36
cT4	17	6
cN stage			-	0.750
cN0	7	4
cN+	79	38
Distance from the anal verge to rectal cancer (cm)			0.061	0.805
≤ 5	45	21
> 5	41	21
Tumor size (cm)			4.317	0.038
≤ 5.75	59	36
> 5.75	27	6
Tumor circumference proportion			0.351	0.554
≤ 1/2	11	7
> 1/2	75	35
Chemotherapy			2.313	0.323
XELOX	59	29
Capecitabine monotherapy	3	4
Others	24	9
Time interval (wk)			-	0.028
≤ 6	12	3
6-10	61	24
> 10	13	15
CEA (ng/mL)			5.288	0.021
≤ 5	43	30
> 5	43	12
CA199 (U/mL)			1.559	0.212
≤ 37	68	37
> 37	18	5
CA125 (U/mL)			-	0.597
≤ 35	84	40
> 35	2	2
CA153 (U/mL)			-	0.550
≤ 25	85	41
> 25	1	1
CA724 (U/mL)			-	0.295
≤ 8	81	37
> 8	5	5
NLR			1.781	0.182
≤ 3.05	65	27
> 3.05	21	15
PLR			0.675	0.411
≤ 117.08	33	13
> 117.08	53	29
LMR			5.528	0.019
≤ 2.73	21	3
> 2.73	65	39
SII			1.640	0.200
≤ 284.51	13	3
> 284.51	73	39
PIV			0.766	0.381
≤ 102.41	13	4
> 102.41	73	38

BMI: Body mass index; CEA: Carcinoembryonic antigen; NLR: Neutrophil to lymphocyte ratio; PLR: Platelet to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; SII: Systemic immune-inflammation index; PIV: Pan immune inflammation value; pCR: Pathologic complete response.